title: [Treatment outcome of non-Hodgkin lymphoma in childhood: KYCCSG NHL-89, 96].
abstract: Two consecutive treatment protocols, NHL-89 and NHL-96, for pediatric diffuse large cell lymphoma (DLC) and lymphoblastic lymphoma (LBL) were conducted between March 1989 and December 2004 by Kyushu-Yamaguchi Children's Cancer Study Group. Forty-two patients (DLC: 15, LBL: 27) and 34 patients (DLC: 8, LBL: 26) were enrolled in NHL-89 and NHL-96, respectively. DLC patients received induction therapy of high-dose methotrexate (MTX) followed by repeated administration of intermediate MTX. LBL patients received a 4-drug induction followed by intensification, consolidation with cranial radiotherapy (15 to 24Gy), and maintenance. The maintenance phase consisted of multiple drug treatment; including prednisolone, vincristine, cyclophosphamide, and 6-mercaptopurine. With a median follow-up of 150 months for NHL-89 and 90.5 months for NHL-96, the estimated event-free survival at 5 years are 76.2±6.6% and 67.7±8.0%, respectively. Both studies improved the prognosis of DLC and LBL over our previous study of NHL-858.
authors.affiliation: Yamaguchi University, Japan.
authors.forename: Reiji
authors.initials: R
authors.lastname: Fukano
authors.forename: Aiko
authors.initials: A
authors.lastname: Suminoe
authors.forename: Akinobu
authors.initials: A
authors.lastname: Matsuzaki
authors.forename: Hiroko
authors.initials: H
authors.lastname: Inada
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Nagatoshi
authors.forename: Eiichi
authors.initials: E
authors.lastname: Ishii
authors.forename: Hideki
authors.initials: H
authors.lastname: Nakayama
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Kawakami
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Moritake
authors.forename: Fumio
authors.initials: F
authors.lastname: Yanai
authors.forename: Nobuyoshi
authors.initials: N
authors.lastname: Itonaga
authors.forename: Soichi
authors.initials: S
authors.lastname: Suenobu
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kikuchi
authors.forename: Jun
authors.initials: J
authors.lastname: Okamura
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Kawano
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality; D016896:Treatment Outcome
chemical_list: D008727:Methotrexate